insights_auto
Por qué ha bajado 4142 6,62%?
Profundizarchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
-6,62%(-1,05) 1 d
20 nov, 13:30:09 GMT+8 · TWD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 4142...
Abrir
15,75 TWD
Alto
15,75 TWD
Bajo
14,80 TWD
Cap. burs.
6356,71 M
Vol. medio
1,13 M
Volumen
1,63 M
Ratio PER
85,76
Máximo en 52 sem.
21,50 TWD
Mínimo en 52 sem.
14,80 TWD
BPA
0,17 TWD
Acciones en circulación
235,29 M
N.º de empleados
564
Abrir
15,75 TWD
Alto
15,75 TWD
Bajo
14,80 TWD
Cap. burs.
6356,71 M
Vol. medio
1,13 M
Volumen
1,63 M
Ratio PER
85,76
Máximo en 52 sem.
21,50 TWD
Mínimo en 52 sem.
14,80 TWD
BPA
0,17 TWD
Acciones en circulación
235,29 M
N.º de empleados
564
Noticias
De fuentes web y partners de noticias
Fortune
·
hace 1 hora
Stock market correction? This chief investment officer sees the S&P 500 soaring 45% to 10,000
The Motley Fool
·
hace 6 horas
The S&P 500 Heads Into Thanksgiving Below Its Peak. Here's How the Holiday Week Has Usually Gone Since 1950.
Beinsure
·
hace 7 horas
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
Yahoo Finance
·
hace 6 horas
T-Bills Are Beating the Nasdaq, S&P 500 and Dow This Year
Perfil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Acerca de Adimmune Corp